In vivo CAR-T's Impressive Streak, AI in Surgery & Cancer Vaccines, + John Boyce @ 28 Capital

In vivo CAR-T keeps stacking wins, AI quietly invades the operating room, and cancer vaccines stage their second act... plus, John Boyce from 28 Capital joins the show. The show will break down the in vivo CAR-T streak that's reshaping how the industry thinks about cell therapy economics, dig into where AI is actually showing up in surgical workflows (and where the hype outpaces the data), and unpack why cancer vaccines are suddenly worth a second look after a decade in the wilderness. Then John Boyce from 28 Capital joins to talk early-stage biotech investing, what's catching his attention right now, and where he thinks the smart money is rotating in 2026.